Ebola Virus Antigen Rapid Test serves as a first-line defense tool in outbreak containment

A severe Ebola outbreak is escalating in Central Africa. As of June 5, 2026, 505 cases and 80 deaths had been reported in the DRC and Uganda. The WHO declared the outbreak a Public Health Emergency of International Concern (PHEIC) on May 17 and raised the DRC’ s national risk level to “Very High Risk” on May 22.1

Understanding the Ebola Virus

Ebola virus disease (EVD) is an acute infection with a high case-fatality rate, transmitted through direct contact with infected blood or body fluids.

Early symptoms are deceptive - fever, headache, and fatigue mimic malaria or flu, making clinical diagnosis nearly impossible. In the current Bundibugyo outbreak, a four-week delay between symptom onset and laboratory confirmation allowed silent community transmission to escalate. Laboratory testing is irreplaceable - only reliable detection can identify infected individuals early.

Ebola virus is a BSL-4 pathogen, requiring specialized facilities for culture. In outbreak and resource-limited settings, antigen detection is the practical solution - rapid, portable, and cost-effective.

It is worth noting that currently no licensed vaccines or specific therapeutics exist for the Bundibugyo strain causing this outbreak. This makes early diagnosis through reliable antigen detection even more critical - as case isolation and contact tracing become the primary line of defense.

MMC' s Ebola Virus Antigen Rapid Test delivers:

● Fast - Results in 15-20 minutes

● Accurate-Qualitatively detects Ebola virus antigen in serum, plasma, or whole blood

● Simple - 2 drops of sample + 2 drops of buffer

● Ready to use - No equipment needed, ideal for field deployment

By enabling early identification of infected individuals, Ebola Virus Antigen Rapid Test serves as a first-line defense tool in outbreak containment.